Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.62 |
| ▸ | NTSR1 | P30989 | 11/20 | 0.60 |
| ▸ | NTSR2 | O95665 | 9/20 | 0.60 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612065 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611692 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611524 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611985 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611528 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29612082 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29611824 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29612137 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL20707335 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL29420258 | 0.98 | NTSR1 (0.60) | NPY1RNPY2RNPY4RNPY5RNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111830154-B | Separation method and application of oxytocin and 8 epimers thereof | 上海上药第一生化药业有限公司 | 2022-05-24 | — | — | CN | claimed |
| CN-111912917-B | Separation method and application of oxytocin and at least ten impurities | 上海上药第一生化药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-20250000947-A1 | OXYTOCIN CONJUGATES FOR TREATING NEONATAL DISORDERS | ELGAN PHARMA LTD (IL) | 2025-01-02 | — | — | US | disclosed |
| CN-119143836-A | Polypeptide cyclization method | 广州医科大学 | 2024-12-17 | — | — | CN | disclosed |
| US-20240391950-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | KAGOSHIMA UNIVERSITY (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-4401793-A1 | OXYTOCIN CONJUGATES FOR TREATING NEONATAL DISORDERS | Elgan Pharma Ltd. (IL) | 2024-07-24 | — | — | EP | disclosed |
| US-20240139278-A1 | OXYTOCIN FORMULATION | XELLIA PHARMACEUTICALS APS (DK) | 2024-05-02 | — | — | US | disclosed |
| EP-4242220-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | Kagoshima University (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230265124-A1 | OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-08-24 | — | — | US | disclosed |
| WO-2023042207-A1 | OXYTOCIN CONJUGATES FOR TREATING NEONATAL DISORDERS | ELGAN PHARMA LTD (IL) | 2023-03-23 | — | — | WO | disclosed |
| US-11414459-B2 | Metabolite inspired selective oxytocin receptor agonists | Kinoxis Therapeutics Pty Ltd (AU) | 2022-08-16 | — | — | US | disclosed |
| CN-111812240-B | Separation method and application of oxytocin and three impurities | 上海上药第一生化药业有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-111830154-B | Separation method and application of oxytocin and 8 epimers thereof | 上海上药第一生化药业有限公司 | 2022-05-24 | — | — | CN | disclosed |
| WO-2022097500-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | 国立大学法人 鹿児島大学 | 2022-05-12 | — | — | WO | disclosed |
| CN-111896642-B | Separation method and application of oxytocin and three kinds of deamidation impurities | 上海上药第一生化药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-111912917-B | Separation method and application of oxytocin and at least ten impurities | 上海上药第一生化药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022040110-A2 | ALKYLATING AGENT AND COMBINATIONS IN THE TREATMENT OF IMMUNE-RELATED AND LIVER DISEASES, ALZHEIMER'S DISEASES AND FIBROSIS DISEASES | LIU SHENG (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391950-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | PTMA, PTMS, CDC37 | NPY1R 564/4885NPY2R 1385/4885NPY4R 1339/4885 |
| US-20240139278-A1 | OXYTOCIN FORMULATION | OXTR, AVPR2, AVPR1B | NPY1R 28/4885NPY2R 26/4885NPY4R 20/4885 |
| US-20230265124-A1 | OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME | OXTR, AVPR2, ADM2 | NPY1R 38/4885NPY2R 42/4885NPY4R 48/4885 |
| US-11414459-B2 | Metabolite inspired selective oxytocin receptor agonists | OXTR, AVPR2, AVPR1A | NPY1R 14/4885NPY2R 16/4885NPY4R 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.